The Motley Fool··Jonathan PoncianoBiohaven Stock Crashes 70%, but $6M Insider Bet Hints at Turnaround Play
Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.
CYTKBHVNNBIXstock declineFDA rejection